Skip to content

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-$189.23M-1,369%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$6.54B+130%
TG Therapeutics logo
TG TherapeuticsTGTX
$5.62B-11.1%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
P/S1,465.1×+962×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's enterprise value?
Dianthus Therapeutics (DNTH) reported enterprise value of $3.82B in Q1 2026.
How has Dianthus Therapeutics's enterprise value changed year-over-year?
Dianthus Therapeutics's enterprise value increased by 564.9% year-over-year, from $574.03M to $3.82B.
What is the long-term trend for Dianthus Therapeutics's enterprise value?
Over 3 years (2022 to 2025), Dianthus Therapeutics's enterprise value has grown at a 254.5% compound annual growth rate (CAGR), from $38.55M to $1.72B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.